The calcium channel antagonists are not an homogeneous group. From both pharmacological and clinical points of view, they can be divided into those of the dihydropyridine family like nifedipine, and those of the non-dihydropyridine family like verapamil and diltiazem. These families bind at different sites to the calcium channel, which may explain some of the clinical differences. The dihydropyridines are more vascular selective and the non-dihydropyridines are more myocardial selective and tend to reduce the heart rate. Further important differences are between short- and long-acting forms of the calcium channel antagonists. From the clinical point of view, these agents are most used in angina pectoris and hyertension. Emerging studies sug...
Calcium channel blockers reduce arterial smooth muscle tone and lower blood pressure. They may be re...
1 Voltage-operated calcium channel (VOCC) antagonists are effective antihypertensive and antianginal...
AbstractAll calcium antagonists have the ability to decrease the symptoms and signs in some patients...
The chief site of action of the calcium antagonist drugs is the slow calcium channel in two tissues:...
Drugs of several chemical families have been identified as calcium antagonists. This article examine...
Voltage-sensitive calcium channels (L-type) mediate the entry of extracellular calcium into smooth m...
The family of calcium antagonist substances is continuously increasing. Often it is difficult, if no...
Calcium antagonists are one of the first line medication in management of hypertension. They inhibit...
This review describes aspects of the calcium recent analysis of slow-onset, long-acting calcium chan...
This paper summarizes the pharmacological properties of calcium channel blockers (CCBs), their estab...
Calcium channel blockers have been used for many yearsin the management of cardiovascular diseases i...
The short- and long-term effects of two calcium channel blocking drugs, verapamil and nifedipine, on...
This article contains information concerning the aspects of pharmacokinetics and pharmacodynamics of...
1. Classical L-type voltage-operated calcium channel (VOCC) antagonists dilate blood vessels, depres...
SUMMARY The development of drugs which selectively block the "slow " channels by which cal...
Calcium channel blockers reduce arterial smooth muscle tone and lower blood pressure. They may be re...
1 Voltage-operated calcium channel (VOCC) antagonists are effective antihypertensive and antianginal...
AbstractAll calcium antagonists have the ability to decrease the symptoms and signs in some patients...
The chief site of action of the calcium antagonist drugs is the slow calcium channel in two tissues:...
Drugs of several chemical families have been identified as calcium antagonists. This article examine...
Voltage-sensitive calcium channels (L-type) mediate the entry of extracellular calcium into smooth m...
The family of calcium antagonist substances is continuously increasing. Often it is difficult, if no...
Calcium antagonists are one of the first line medication in management of hypertension. They inhibit...
This review describes aspects of the calcium recent analysis of slow-onset, long-acting calcium chan...
This paper summarizes the pharmacological properties of calcium channel blockers (CCBs), their estab...
Calcium channel blockers have been used for many yearsin the management of cardiovascular diseases i...
The short- and long-term effects of two calcium channel blocking drugs, verapamil and nifedipine, on...
This article contains information concerning the aspects of pharmacokinetics and pharmacodynamics of...
1. Classical L-type voltage-operated calcium channel (VOCC) antagonists dilate blood vessels, depres...
SUMMARY The development of drugs which selectively block the "slow " channels by which cal...
Calcium channel blockers reduce arterial smooth muscle tone and lower blood pressure. They may be re...
1 Voltage-operated calcium channel (VOCC) antagonists are effective antihypertensive and antianginal...
AbstractAll calcium antagonists have the ability to decrease the symptoms and signs in some patients...